Use PTSR and LOA information and event-driven changes for your investment decisions to generate alpha KX-826 is an androgen receptor (AR) antagonist and a potential first-in-class topical drug for the treatment of AGA and acne vulgaris. For the AGA indication, in September 2021, Kintor Pharma announced the primary endpoint of the phase II clinical trial of KX-826 on male adults was met, with results demonstrating a positive efficacy and safety profile. Since then, Kintor has released several other press releases stating the details of its results. Both its female phase II pyrilutamide clinical trial and its American phase II pyrilutamide trial for male pattern hair loss showed promising results. Pyrilutamide Side Effects

0.5% Pyri topical (60 ml) – HAIRLICIOUSLY

Pyrilutamide is a topical anti-androgen. The clinical trials done so far have shown that it does not decrease systemic androgen levels. Thus, it is unlikely to cause unwanted adverse drug reactions that are usually seen in patients using oral 5-alpha reductase inhibitors – decreased libido, erectile dysfunction, and depression being the most notable ones. Store in a cool, dark place. Pyrilutamide solution maintains potency for at least two years upon mixing. Expiry date is displayed on label and only bottles with one year or more before this are shipped. A recently completed phase-1 clinical trial done in the US was a randomized, double-blind, placebo-controlled, parallel-group, and dose-escalation study. It involved 40 healthy adult male patients with androgenetic alopecia. Based on the data from clinical trials, pyrilutamide 0.5% solution has to be applied once daily for female AGA and twice daily for male AGA to get best results. Side effects of pyrilutamide A derma pen from experience feels different even at 1mm to say a derma roller and that's why it's sometimes best to start off with a depth that's not causing you too much discomfort.KX-826 is an androgen receptor (AR) antagonist and a potential first-in-class topical drug for the treatment of AGA and acne vulgaris. KX-826 has showed good efficacy and safety profile in the phase II clinical trial in China for the treatment of AGA male patients. The most detailed pyrilutamide clinical trial results currently available come from press releases and a poster created for the Annual Meeting of the Chinese Hair Research Society sponsored by the Chinese Society of Dermatology. According to this poster presentation, 120 Chinese men with moderate pattern hair loss symptoms (Norwood-Hamilton classification IIIv, IV, or V) enrolled in this phase II clinical trial. And it does get into the bloodstream so they tried lower dosages then the amount that gets into bloodstream is very low.

Pyrilutamide - A Game Changer In the Making? - Hair Pyrilutamide - A Game Changer In the Making? - Hair

Kinter, K. J., & Anekar, A. A. (2022). Biochemistry, dihydrotestosterone. In StatPearls [Internet] . StatPearls Publishing.Do you guys feel like we may even get some interesting combination treatments with people showing amazing results maybe even combining Finasteride and Pyrilutamide? In terms of saving hair or regrowth, almost no treatment out there guarantees that. It just so happens we have anecdotal evidence that people using the "Big 3" of Finasteride, Minoxodil and Microneedling with perhaps a side of Nizoral containing 2% ketoconazole have shown regrowth. So there's a possibility this could help too but from a legal and marketing PoV, it's better to protect themselves by not saying that's a benefit of the product. Developing Novel Drugs and Commercialization Platform, Kintor Pharma, 2022. Accessed online: https://docs.publicnow.com/viewDoc?hash_primary=BFD6444A4669BD4BE0683A8BCC8B5E80F3D7E430

Pyrilutamide vs RU58841? Or use both concurrently? Pyrilutamide vs RU58841? Or use both concurrently?

I would be seriously interested to see if there's any chance whatsoever that when DHT bindings at the Androgen Receptor are cut, whether even people with "dead zones" usually considered past the 50% point of miniaturisation might show regrowth with this new or combined treatments. In November 2021, the Phase-3 clinical trial protocol for pyrilutamide to treat male androgenetic alopecia was greenlighted. A randomized, double-blind, placebo-controlled, multi-regional phase-3 clinical trial will be done in 26 dermatology centers in China. INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED 30 JUNE 2022, KINTOR PHARMACEUTICAL LIMITED (2022). Accessed online: https://www1.hkexnews.hk/listedco/listconews/sehk/2022/0829/2022082902004.pdf

Share your story

a b c CApatent 2829322,Tong Y,"Substituted Thioimidazolidinone Androgen Receptor Antagonists and Uses Thereof",published 2012-03-08,issued 2017-01-10, assigned to Suzhou Kintor Pharmaceuticals, Inc Dominguez‐Santas M, Diaz‐Guimaraens B, Saceda‐Corralo D, Hermosa‐Gelbard A, Muñoz‐Moreno Arrones O, Pindado‐Ortega C, Fernandez‐Nieto D, Jimenez‐Cauhe J, Ortega‐Quijano D, Suarez‐Valle A, Jaen‐Olasolo P. (2022). The state‐of‐the‐art in the management of androgenetic alopecia: A review of new therapies and treatment algorithms. JEADV Clinical Practice.

Pyrilutamide KX826 and Hair Growth | The Hair Loss Show Pyrilutamide KX826 and Hair Growth | The Hair Loss Show

Yes, hair regrowth unfortunately is something that's eluding us with only cases where male to female transitions are taking place and that level of pharmacology seems to show anecdotally complete regrowth of hair. Obviously not something a majority of biological males wishing to remain so would ever consider but i do actually agree with you that combining this with Finasteride could show a strong synergistic element but only time will tell. Hirshburg, J. M., Kelsey, P. A., Therrien, C. A., Gavino, A. C., & Reichenberg, J. S. (2016). Adverse effects and safety of 5-alpha reductase inhibitors (finasteride, dutasteride): a systematic review. The Journal of clinical and aesthetic dermatology, 9(7), 56. KX-826 (pyrilutamide) is first androgen receptor antagonist which has entered phase III clinical trial for male androgenetic alopecia treatment in China and global. Primary endpoint of KX-826 on male AGA patients met and demonstrated outstanding efficacy and safety profile. All i know is that we're long overdue true new treatments for Androgenic Alopecia and they can't come soon enough.

For female pattern hair loss, only topical minoxidil is FDA-approved. However, both of these drugs have a few limitations and side effects. Hair transplantation works well but is expensive. Topical clascoterone 7.5% solution (Breezula) is another topical androgen receptor inhibitor undergoing clinical trials. Pyrilutamide’s mechanism of action It does seem like it's so far proving very effective in terms of the clinical trial data for hair loss and i do think for a lot of guys it will be interesting to see if it could possibly replace both Finasteride and Minoxodil as a combination treatment to just relying on a single treatment for those suffering hair loss in the early stages. Kintor Pharma Announces the Primary Endpoint of Phase II Clinical Study for KX-826's Treatment of Androgenetic Alopecia Was Met". As of March 2023, 740 male patients have been enrolled in this study. This study is designed to evaluate the efficacy and safety profile of pyrilutamide for male pattern hair loss. The trial duration is 24 weeks with a 4-week follow-up. The primary endpoint is to see the change in non-vellus TAHC from baseline at the end of week 24. The results are expected by December 2023. How to use pyrilutamide?